Englander Institute for Precision Medicine

Publications

Found 692 results
Author [ Title(Desc)] Type Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
C
Gao VR, Yang R, Das A, Luo R, Luo H, McNally DR, Karagiannidis I, Rivas MA, Wang Z-M, Barisic D et al..  2023.  ChromaFold predicts the 3D contact map from single-cell chromatin accessibility.. bioRxiv.
Tang F, Xu D, Wang S, Wong CKhuan, Martinez-Fundichely A, Lee CJ, Cohen S, Park J, Hill CE, Eng K et al..  2022.  Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets.. Science. 376(6596):eabe1505.
Vitale I, Galassi C, Galluzzi L.  2024.  Chromosomal instability drives immunosuppression and metastatic dissemination.. Cell Res. 34(1):7-8.
Hwang I, Pan H, Yao J, Elemento O, Zheng H, Paik J.  2020.  CIC is a critical regulator of neuronal differentiation.. JCI Insight. 5(9)
Kasi PM, Lee JK, Pasquina LW, Decker B, Borre PVanden, Pavlick DC, Allen JM, Parachoniak C, Quintanilha JCF, Graf RP et al..  2024.  Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types.. Clin Cancer Res. 30(4):836-848.
Chennamadhavuni A, Kasi PMurtaza.  2022.  Circulating Tumor DNA in Identifying Resistant Sub-Clones Post EGFR Blockade: Implications for EGFR Rechallenge.. Front Oncol. 12:847299.
Beltran H, Romanel A, Conteduca V, Casiraghi N, Sigouros M, Franceschini GMarco, Orlando F, Fedrizzi T, Ku S-Y, Dann E et al..  2020.  Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer.. J Clin Invest. 130(4):1653-1668.
Iacono A, Pompa A, De Marchis F, Panfili E, Greco FA, Coletti A, Orabona C, Volpi C, Belladonna ML, Mondanelli G et al..  2020.  Class IA PI3Ks regulate subcellular and functional dynamics of IDO1.. EMBO Rep. 21(12):e49756.
Kolin DA, Kulm S, Elemento O.  2020.  Clinical and Genetic Characteristics of Covid-19 Patients from UK Biobank.. medRxiv.
Conteduca V, Oromendia C, Eng KW, Bareja R, Sigouros M, Molina A, Faltas BM, Sboner A, Mosquera JMiguel, Elemento O et al..  2019.  Clinical features of neuroendocrine prostate cancer.. Eur J Cancer. 121:7-18.
Jobanputra V, Wrzeszczynski KO, Buttner R, Caldas C, Cuppen E, Grimmond S, Haferlach T, Mullighan C, Schuh A, Elemento O.  2022.  Clinical interpretation of whole-genome and whole-transcriptome sequencing for precision oncology.. Semin Cancer Biol. 84:23-31.
Higano CS, George DJ, Shore ND, Sartor O, Miller K, Conti PS, Sternberg CN, Saad F, Sade JPablo, Bellmunt J et al..  2023.  Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancer.. EClinicalMedicine. 60:101993.
Sailer V, Gevensleben H, Dietrich J, Goltz D, Kristiansen G, Bootz F, Dietrich D.  2017.  Clinical performance validation of PITX2 DNA methylation as prognostic biomarker in patients with head and neck squamous cell carcinoma.. PLoS One. 12(6):e0179412.
Kolin DA, Kulm S, Christos PJ, Elemento O.  2020.  Clinical, regional, and genetic characteristics of Covid-19 patients from UK Biobank.. PLoS One. 15(11):e0241264.
Bekheirnia N, Glinton KE, Rossetti L, Manor J, Chen W, Lamb DJ, Braun MC, Bekheirnia MReza.  2021.  Clinical Utility of Genetic Testing in the Precision Diagnosis and Management of Pediatric Patients with Kidney and Urinary Tract Diseases.. Kidney360. 2(1):90-104.
Rosenquist R, Cuppen E, Buettner R, Caldas C, Dreau H, Elemento O, Frederix G, Grimmond S, Haferlach T, Jobanputra V et al..  2022.  Clinical utility of whole-genome sequencing in precision oncology.. Semin Cancer Biol. 84:32-39.
Fontugne J, Davis K, Palanisamy N, Udager A, Mehra R, McDaniel AS, Siddiqui J, Rubin MA, Mosquera JMiguel, Tomlins SA.  2016.  Clonal evaluation of prostate cancer foci in biopsies with discontinuous tumor involvement by dual ERG/SPINK1 immunohistochemistry.. Mod Pathol. 29(2):157-65.
Faltas BM, Prandi D, Tagawa ST, Molina AM, Nanus DM, Sternberg C, Rosenberg J, Mosquera JMiguel, Robinson B, Elemento O et al..  2016.  Clonal evolution of chemotherapy-resistant urothelial carcinoma.. Nat Genet. 48(12):1490-1499.
Kaner J, Desai P, Mencia-Trinchant N, Guzman ML, Roboz GJ, Hassane DC.  2020.  Clonal Hematopoiesis and Premalignant Diseases.. Cold Spring Harb Perspect Med. 10(4)
Meleshko D, Prjbelski AD, Raiko M, Tomescu AI, Tilgner H, Hajirasouliha I.  2024.  cloudrnaSPAdes: isoform assembly using bulk barcoded RNA sequencing data.. Bioinformatics. 40(2)
Meleshko D, Prjbelski AD, Raiko M, Tomescu AI, Tilgner H, Hajirasouliha I.  2023.  cloudrnaSPAdes: Isoform assembly using bulk barcoded RNA sequencing data.. bioRxiv.
Dutta A, Panja S, Virk RK, Kim JYeji, Zott R, Cremers S, Golombos DM, Liu D, Mosquera JMiguel, Mostaghel EA et al..  2017.  Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5α-reductase Inhibition.. Eur Urol. 72(4):499-506.
Rivas MA, Durmaz C, Kloetgen A, Chin CR, Chen Z, Bhinder B, Koren A, Viny AD, Scharer CD, Boss JM et al..  2021.  Cohesin Core Complex Gene Dosage Contributes to Germinal Center Derived Lymphoma Phenotypes and Outcomes.. Front Immunol. 12:688493.
Fontugne J, Cai PY, Alnajar H, Bhinder B, Park K, Ye H, Beg S, Sailer V, Siddiqui J, Blattner-Johnson M et al..  2022.  Collision tumors revealed by prospectively assessing subtype-defining molecular alterations in 904 individual prostate cancer foci.. JCI Insight. 7(4)
Li S, Wong A, Sun H, Bhatia V, Javier G, Jana S, Wu Q, Montgomery RB, Wright JL, Lam H-M et al..  2024.  A combinatorial genetic strategy for exploring complex genotype-phenotype associations in cancer.. Nat Genet. 56(3):371-376.